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Abstract
Schizophrenia is usually a progressive mental illness with very different polymorphic 
symptoms. Several different theories of schizophrenia were discussed; the causes of 
this disease are not yet clear. Destruction of DNA, RNA, and myelin basic protein 
(MBP) by inflammation caused by autoimmune reactions has been revealed. Healthy 
humans usually do not develop abzymes. It was shown that DNase, RNase, and 
MBP-hydrolyzing abzymes are easily detectable at the beginning of different autoim-
mune diseases (AIDs). During the development of spontaneous and induced AIDs in 
mice, a specific reorganization of their immune system associated with the generation 
of abzymes hydrolyzing different autoantigens was revealed. SCZ is currently not 
assigned to classical autoimmune diseases. However, the sera of approximately 30% 
of SCZ patients demonstrated a high level of anti-DNA Abs (comparing to 37% of SLE 
patients); abzymes hydrolyzing DNA, RNA, and MBP were revealed in 80–100% of 
SCZ patients. The site-specific hydrolysis of four known SCZ-specific microRNA play-
ing an important role in the regulation of several genes functioning was revealed. Anti-
MBP IgGs hydrolyze specifically only MBP but not other proteins. The data indicate 
that SCZ patients may to a certain extent show similar to SLE and MS patients’ typical 
signs of autoimmune processes.
Keywords: schizophrenia, autoimmunity, catalytic antibodies, hydrolysis of 
autoantigens
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1. Introduction
Schizophrenia (SCZ) is a highly heritable brain disorder, and it is one of the most relevant 
problems of psychiatry [1]. The prevalence of SCZ in the human population is approximately 
1%, and this disease is the most severe mental diseases [2]. Schizophrenia is a progressive 
mental illness demonstrating polymorphic symptomatology and resulting in the persistent 
violation of social adaptation and ability to work. In SCZ, a violation of synaptic transmission 
resulting in neuronal damage and severe dysfunction was observed [3–5]. These changes often 
may begin to arise in utero or early childhood [6, 7].
Several different theories of SCZ were discussed, but all of them cannot be definitively con-
cluded for or against the degenerative or neurodevelopmental hypothesis and did not pro-
vide clarity concerning the mechanism of schizophrenia development [8].
The dopamine hypothesis of schizophrenia is a model, attributing symptoms of SCZ to a 
disturbed and hyperactive dopaminergic signal transduction. Since dysfunction of the glu-
tamatergic system is a widely known fact in SCZ [9–12], it is possible that misbalance of 
dopamine-glutamate homeostasis can lead to the patient’s development of generalized oxida-
tive stress [13, 14]. The known theory, however, does not posit dopamine overabundance as 
a complete explanation of SCZ. Rather, the overactivation of D2 receptors, specifically, is one 
effect of the global chemical synaptic dysregulation observed in this disorder.
Detection of neurotropic effect which was postulated is associated with the damages of cell 
membranes [15, 16]. It is believed that the brain cell membranes damage causes the forma-
tion of autoantigens and as the consequence autoantibodies (Abs) [17–19]. Interestingly, 
Abs to glutamate receptors were revealed in SCZ and many other diseases including typi-
cal autoimmune ones [20]. Anti-NMDA-NR1, anti-AMPA-GluR3, anti-NMDA-NR2A/B, and 
anti-mGluR1 or anti-mGluR5 antibodies were found in subpopulations of patients not only 
with SCZ but also with encephalitis, epilepsy, SLE, neuropsychiatric SLE, cerebellar ataxia, 
Sjogren’s syndrome, and mania or stroke [20]. These autoimmune Abs against anti-glutamate 
receptors can bind neurons in few brain regions, activate receptors of glutamate, decrease 
glutamate receptor’s expression, activate blood-brain barrier endothelial cells, damage the 
brain, impair glutamate-induced signaling and function, kill neurons, and induce psychiatric/ 
behavioral/cognitive abnormalities [20]. The association between SCZ and various inflammatory- 
autoimmune diseases was reported in several epidemiological surveys. Several studies dem-
onstrated that individuals with SCZ are somehow less likely to have rheumatoid arthritis [21]. 
Some other autoimmune (AI) disorders have also been linked to schizophrenia, particularly 
Hashimoto’s thyroiditis and celiac disease [22, 23].
During the last decade, new data about increasing recognition of central nervous system 
(CNS) syndromes associated with autoimmune processes leading to the production of auto-
antibodies to CNS cell surface antigens were obtained [24]. Most of these syndromes present 
outstanding mental and cognitive symptoms, among the variety of neurological manifesta-
tions such as seizures, movement disorders, and autonomic dysfunction, and is best described 
as “autoimmune encephalopathy.”
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The causes of schizophrenia include environmental and genetic factors [25]. Recently, a 
genome-wide microarray study in postmortem brains of SCZ patients has explored expression 
profiling of immune-modulatory genes [26]. Genetic factors in SCZ include a variety of com-
mon and rare genetic variants [27]. It was shown that SCZ is a multifactorial disease, the patho-
genesis of which can contribute to numerous genes and the products of their transcription 
[28]. Therefore, in research of schizophrenia pathogenesis, understanding a possible role of 
microRNAs may be important. Short non-coding microRNAs (18–25 nucleotides) can individ-
ually regulate up to several hundred genes. Disturbances in microRNA (microRNA-regulated 
gene network) lead to alteration in the expression of many genes. The expression of different 
microRNAs in plasma [29, 30], mononuclear cells of peripheral blood [31] as well as in various 
brain regions [32, 33] in patients with SCZ was detected. In addition, genome-wide association 
study shows, in SCZ, a close association of a single-nucleotide polymorphism of miR-137 and 
miR-9-5p [34–36]. MicroRNA miR-137 plays an important role in the differentiation of embry-
onic stem cells, proliferation, and differentiation of neurons, the maturation of the synapses 
[37]. The miR-137 inhibits AMPA receptor-mediated synaptic transmission by decreasing the 
expression of the GluA1 subunit of this receptor [38]; influences the release of neurotransmit-
ters from synaptic vesicles and disrupts synaptic plasticity [39]. Interestingly, one of the genes 
regulating the expression of miR-137, is a protein zinc finger 804А (zinc finger protein 804 
A-ZNF804A), which in turn inhibits the expression of catechol-O-methyltransferase (catechol-
O-methyltransferase), and D2 receptor of dopamine [37], which leads to a disruption in dopa-
mine neurotransmission. In the regulation of expression of the D2 receptor of dopamine is also 
involved in the miR-9-5p [36]. It is shown that miR-9-5p is involved in neuronal migration and 
that the expression of miR-9-5p in patients with schizophrenia is reduced in neuronal cells 
precursors (neural progenitor cells) [40]. It was also found that miR-219 plays an important 
role in the differentiation of oligodendrocytes and myelination of axons of neuronal cells [41].
It is known that enzymes can play important role in the pathogenesis of different diseases: 
dysfunction of enzymes systems involved in the metabolism of biogenic amines (indolamine, 
catecholamines) during mental disorders including SCZ [23, 42].
The above data testify to the fact that some patients with SCZ are clearly showing signs of 
typical autoimmune pathologies. However, the importance of immunological changes result-
ing in the loss of the tolerance to self-antigens in the pathogenesis of SCZ is currently not 
accepted. Summarizing all existing hypotheses, one can say that SCZ is a very multifactorial 
disease including some variations in the functioning of neurotransmitter systems associated 
with the changes in the rate of synthesis or breakdown of the neurotransmitter, possible mod-
ifications of the structure of the relevant receptors, genetic predisposition and a dysregulation 
between the immune and nervous systems, important role of genetic factors and microRNAs, 
as well as enzymatic systems.
Despite the fact that SCZ is not currently attributed to typical autoimmune diseases, the 
immune system and dysregulation of immune cells, including autoimmune processes in this 
disease, are not to be excluded [17–20, 24]. Schizophrenia, autoimmunity and immune system 
dysregulation are reviewed in [43, 44]. Thus, the search of the importance of different mecha-
nisms of SCZ development including possible autoimmune factors is undoubtedly actual. In this 
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connection, some literature data should be mentioned. Catalytically active artificial antibodies 
or abzymes (Abzs) against transition chemical reaction states were well studied (reviewed in 
[45–47]). In the last three decades, it was shown that auto-antibodies from the blood of patients 
with different AIDs can possess enzymatic activities and that their occurrence is a specific fea-
ture of these pathologies (reviewed in [47–53]). Similarly to artificial Abzs to transition states of 
chemical reactions [45–47], natural abzymes are Abs raised directly against enzyme substrates 
acting as haptens of proteins mimicking transition states of catalytic reactions. In addition, anti-
idiotypic Abs against catalytic centers of enzymes can be induced in AIDs, and they also possess 
catalytic activities [47–56].
Even in the sera of healthy mammals, auto-antibodies to different peptides, proteins, DNA, 
and RNA are detectable, and their titers vary significantly [47–57]. The sera of SLE patients 
usually contain DNA and anti-DNA Abs in increased concentrations, and SLE is usually con-
sidered to be associated with the autoimmunization of patients with DNA. However, the 
sera of patients with several different autoimmune diseases contain DNA and anti-DNA Abs 
[57], as well as RNA and anti-RNA Abs in high concentrations [58–61]. Many anti-DNA Abs 
are directed against histone-DNA nucleosomal complexes appearing from internucleosomal 
cleavage during apoptosis [62].
Despite the fact that the blood of healthy donors usually contains autoantibodies to DNA, 
RNA, and many different proteins, these Abs usually do not possess catalytic activities 
[47–56]. It was shown, that in the case of different autoimmune patients, experimental mice 
abzymes with DNase, protease, and amylase activities are the earliest and statistically signifi-
cant markers of autoimmune pathology onset and following development [63–69]. Enzymatic 
activities of Abs are detectable even at the stage of pre-disease when there is no visible mark-
ers of autoimmune diseases and changes in proteinuria, and the anti-antigen titers including 
DNA and proteins are within the typical ranges of these indicators for healthy humans and 
experimental mice [63–69]. Therefore, a detectable level of Ab activities can be considered as 
valuable index even at the beginning of the pathology (pre-disease) and obvious pathology 
conditions of spontaneous or induced autoimmune diseases [63–69].
Natural polyclonal IgGs and/or IgAs and IgMs hydrolyzing mononucleotides, DNA, RNA, oli-
gopeptides, proteins, and polysaccharides, from the sera of patients with several AIDs and sev-
eral viral diseases with significant autoimmune reactions were revealed (reviewed in [47–56]). 
Bence-Jones proteins of multiple myeloma patients [70], DNase abzymes from SLE [71] and MS 
[51] are cytotoxic, induce nuclear DNA fragmentation and cause cell death by apoptosis, lead-
ing to increase in the concentration of many different cell components including DNA, RNA, 
and proteins in patients with various AIDS. Abzymes with RNase activity in autoimmune dis-
eases are of particular interest. The same polyclonal preparations of Abzs hydrolyzed RNA 
approximately 10-fold to 300-fold faster than DNA [72–74].
It has been recently shown that myelin basic protein (MBP)-hydrolyzing activity is an intrin-
sic property of IgGs of SLE patients [75–78] as well as IgGs, IgMs, and IgAs from the sera of 
MS patients [79–82]. In MS and SLE, anti-MBP abzymes with protease activity can attack MBP 
of the myelin-proteolipid sheath of axons and can play an important harmful role in MS and 
SLE pathogenesis [75–82].
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In this review, an analysis of the catalytic  activities of currently described abzymes in the 
blood of patients with SCZ was carried out. These abzymes of SCZ with different catalytic 
activities are compared with other Abzs in AIDs. In addition, a possible role of defects of 
immune systems leading to the production of abzymes is discussed.
Taking into accoIn this review, an analysis of the catalytic activities of currently described 
abzymes in the blood of patients with SCZ. These abzymes of SCZ with different catalytic 
activities are compared with other Abzs in AIDs. In addition, a possible role of defects of 
immune systems leading to the production of abzymes is discussed.unt the ability of auto-
immune patient’s abzymes to hydrolyze RNA together with the important role of microR-
NAs in proliferation, differentiation, and maturation of neuronal cells and the relationship 
of microRNAs with the development of SCZ, the aim of present chapter was to analyze the 
RNA-hydrolyzing activity of Abs of schizophrenia patients. In addition, we have described 
substrate specificity antibodies in the hydrolysis of specific for schizophrenia microRNA.
As mentioned above, schizophrenia is not attributed to the classic autoimmune diseases. At 
the same time, it was recently shown that the sera of ~30% of SCZ patients showed a higher 
content of anti-DNA Abs (comparing to 37% of SLE patients), while DNase abzymes were 
revealed in 80% of SCZ patients [83]. In addition, it was shown that abzymes hydrolyzing 
MBP were revealed in 82% of the SC patients. These data can indicate for at least a pro-
nounced autoimmune component in patients with SCZ. Interestingly, the researchers of the 
London medical Institute Oliver House advanced theory, according to which schizophrenia 
is the result of a lesion of immune system of the brain (http://the-newspapers.com/2017/11/08/
schizophrenia-has-announced-a-disease-of-the-immune-system).
2. Abzymes with DNase activity
The generation of auto-Abs to DNA usually occurs not only in patients with AI, viral, and 
bacterial diseases but also in healthy humans [23, 24, 32–35, 55]. We have compared the rela-
tive levels of Abs interacting with DNA in sera of 20 SCZ patients and 20 healthy donors. The 
levels of Abs interacting with single-stranded (ss) DNA (A450/ml) for 20 healthy donors were detectable; they varied from 0.07 to 0.14 specific units (average value—0.13 ± 0.02) and, on 
average, they were 1.3-fold higher (P = 6.3 × 10−4) than those interacting with double-stranded 
(ds) DNA varying from 0.1 to 0.18 (0.1 ± 0.02) [83, 84]. The average level of Abs (A450/ml) for the total group of patients with SCZ interacting with ssDNA (range from 0.1 to 1.4; average 
value 0.23 ± 0.13) was only 1.1-fold lower (P = 6.9 × 10−4) than that for interacting with dsDNA 
(range from 0.15 to 0.44; average value 0.25 ± 0.07). The average level of Abs interacting with 
dsDNA for healthy donors is 2.5-fold lower (P = 1.0 × 10−6) than that for SCZ patients, while for 
antibodies interacting with ssDNA, it is lower only 1.8-fold (P = 0.05). Several SCZ patients are 
characterized by very high levels of Abs interacting with ssDNA and dsDNA (0.31–1.4 A450/ml) characterizing patients with SLE (0.51 ± 0.50 and 0.66 ± 0.48 A450/ml, respectively) and with MS (0.22 ± 0.18 and 0.39 ± 0.26 A450/ml, respectively) [53–56].
The average relative level of Abs interacting with dsDNA (0.23 ± 0.05 A450/ml) for SCZ patients with positive symptoms was 1.2-fold lower than that for patients with negative symptoms 
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(0.28 ± 0.07 A450/ml) (Table 2). At the same time, the average level of Abs interacting with ssDNA (0.3 ± 0.22 A450/ml) for patients with positive symptoms was 1.9-fold higher than that for SCZ patients demonstrating negative symptoms (0.16 ± 0.07 A450/ml). It was accepted that increased concentration of anti-DNA Abs is a characteristic of patients with SLE. However, 
concentration of anti-DNA Abs compared with healthy donors is higher in patients with SLE 
(37% of patients), MS (17–18%), Sjogren’s syndrome (18%), Hashimoto thyroiditis (23%), 
rheumatoid arthritis (7% of patients), and myasthenia gravis (6%) [57]. Overall, ~30% of SCZ 
patients (comparable with SLE patients 37% [57]) displayed higher content of Abs interacting 
with ss- and dsDNA when compared to healthy donors.
As mentioned above, polyclonal natural DNA-hydrolyzing IgGs and/or IgAs and IgMs were 
revealed in blood sera of patients with several AI and viral diseases (reviewed in [47–57]). 
Electrophoretically and immunologically homogeneous IgGs were obtained from the sera 
of 20 SCZ patients and 20 healthy volunteers by sequential chromatography of the serum 
proteins on Protein A-Sepharose using conditions providing removing non-specifically 
bound proteins, followed by FPLC gel filtration in an acidic buffer destroying immune com-
plexes as in [75–81]. For some experiments, equimolar mixtures of 20 IgG preparations of 
SCZ patients (scz-IgGmix) and 20 preparations of healthy donors (healthy-IgGmix) were used [83]. To show that IgGs of SCZ patients possess DNase activity, we have checked several 
known strict criteria [52–56, 85]. The following main criteria were used [83]: (a) Abs should 
be electrophoretically homogeneous (Figure 1A); (b) Abs after gel filtration in an acidic buf-
fer (pH 2.6) dissociating strong noncovalent complexes IgGs must possess DNase activ-
ity and the peak of the activity should tracked exactly with the intact Abs (Figure 1B); (c) 
immobilized polyclonal antibodies against the human Abs should completely absorb the 
DNase activity; (d) among criteria, there is an hardest one; if it is carried out, all other cri-
teria are also met. To exclude any possible artifacts due to hypothetical traces of contami-
nating canonical DNases, scz-IgGmix preparation was subjected to SDS-PAGE in a gel containing polymeric DNA, and its DNase activity was analyzed after gel incubation in the 
standard reaction buffer (Figure 1C). Ethidium bromide staining of the gels revealed sharp 
dark bands against a fluorescent DNA background only in the position of intact IgGmix  before (lane 3) and only in the position of light chains after Abs reduction with DTT (lane 4). 
There was no revealed DNase activity of healthy-IgGmix before (lane 5) and after Abs reduction with DTT (lane 6).
The intact IgGs have molecular masses (~150 kDa) significantly higher than for all canonical 
human DNases (35–36 kDa), while DNases have higher molecular masses than light chains 
of IgGs (22–25 kDa). SDS usually dissociates all protein complexes. The detection of DNase 
activity only in the gel zones of intact IgGs and their light chains as well as the absence of any 
other activity and protein bands (Figure 1C) ensure direct evidence that SCZ IgGs hydrolyze 
DNA and are not contaminated with canonical DNases. Several other strict criteria were also 
fulfilled (see below).
We have shown that the DNase activity of IgGs purified by chromatography on Protein 
G-Sepharose followed by FPLC gel filtration can be used for the evaluation of their relative 
activity (RA) without additional purification. The RAs of SCZ patients IgGs were significantly 
varied from patient to patient. However, 16 of 20 samples (80%) had high or detectable DNase 
activity. The distributions of the RAs for IgGs of different SCZ patients with positive and 
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negative symptoms are shown in Figure 1D. Finally, to compare RAs of DNase IgGs of SCZ 
patients with those for patients with other diseases, the values of apparent k
cat
 in the hydro-
lysis of DNA for every IgG preparation (k
cat
 = V (M/min)/ [IgGs] (M) and average values of 
parameters were calculated (Table 1) [83].
Figure 1. SDS-PAGE analysis of IgGmix (7 μg) corresponding to the mixtures of scz-IgGmix (lane 2) from the sera of 20 patients with SCZ and healthy-IgGmix (lane 3) corresponding to 20 healthy donors in a nonreducing 3–16% gradient gel or in a reducing 12% gel (lanes 4 and 5, respectively) followed by silver staining (A); the lane 1 arrows indicate the positions 
of molecular mass markers. The application of the strict criteria is to prove that the DNase activity of Abs is the intrinsic 
property of scz-IgGmix. FPLC gel filtration of scz-IgGmix on a Superdex 200 column using an acidic buffer (pH 2.6) after IgGs pre-incubation in the same buffer (B): (■), relative activity (RA, %) of IgGs in the hydrolysis of supercoiled DNA; 
(—), absorbance at 280 nm (A280). A complete hydrolysis of 18 μg/ml scDNA for 2 h was taken for 100%. The initial rate 
determination error from three experiments in each case did not exceed 7–10%. Assay of DNase activity of scz-IgGmix from schizophrenia patients in-gel containing thymus DNA before (lane 3) and after IgGs reduction with DTT (lane 4); 
lane 5 corresponds to healthy-IgGmix before treatment with DTT (C). DNase activity was revealed after gel staining with 
ethidium bromide as a dark band on the fluorescent background. There was no revealed catalytic activity of healthy-
IgGmix before its reduction (lane 5). A part of the used gel was stained with Coomassie R250 to find the position of intact scz-IgGmix before (lane 1) as well as its free heavy and light chains after Ab reduction (lane 2). The distribution of the RAs (in the hydrolysis of scDNA) corresponding to SCZ patients with positive and negative symptoms within different ranges 
(D). The median (M; solid lines) and interquartile ranges (IQR) were estimated using the Mann-Whitney test.
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One of the criteria of Abs’ activity is their higher affinity for substrates comparing with canon-
ical DNases. The K
m
 and k
cat
 values for scDNA hydrolysis were estimated. First, IgG-19 corre-
sponds to the patient with negative symptoms (NS) of SCZ, while IgG-1 and IgG-6 to patients 
with positive symptoms (Table 1). The K
m
 value for IgG-19 (K
m
 = 95 ± 18 nM) was comparable 
with that for IgG-1 (K
m
 = 85.0 ± 12.0 nM) and IgG-6 (K
m
 = 80.0 ± 12.0 nM), while k
cat
 for IgG-19 
((2.7 ± 0.3) × 10−3 min−1) and IgG-6 ((3.0 ± 0.3) × 10−3 min−1) were comparable, but lower than 
that for IgG-1 ((7.9 ± 0.5) × 10−3 min−1). Thus, the affinity of scDNA for SCZ IgGs was in the 
range 80–95 nM, which corresponds to typical K
d
 (and K
m
) values for interactions of antibod-
ies with antigens; it is approximately 3–4 orders of magnitude higher than affinity of DNase I 
for scDNA (K
m
 = 46–58 μM) [86].
Number of patients (sex) Abs to dsDNA, 
A
450
/ml
Abs to ssDNA, 
A
450
/ml
Relative hydrolysis of 
DNA, %
k
cat
 ×105,min−1
1 2 3 4
Positive symptoms (PS)
1 (M) 0.35 1.4 257μ 39.6***
2 (M) 0.19 0.11 11.7 1.8
3 (M) 0.2 0.31 22.2 3.4
4 (M) 0.19 0.16 11 1.7
5 (M) 0.24 0.19 12 1.9
6 (M) 0.15 0.11 100.4 15.5
7 (M) 0.21 0.14 112 17.3
8 (F) 0.2 0.23 22 3.4
9 (F) 0.34 0.25 13 2.0
10 (F) 0.18 0.11 0 0
Average (PS) 0.23±0.05 0.30±0.22 56.1±60.2 8.7±9.3
M (IQR) (PS)ϒ 0.20 (0.05) 0.18 (0.14) 17.5 (88.7) 2.7 (13.7)
Correl. coeff. (PS) Groups 1–2 (0.71) 1–3 (0.46) 2–3 (0.84)
Negative symptoms (NS)
11 (M) 0.48 0.23 0μ 0
12 (M) 0.28 0.2 0 0
13 (M) 0.21 0.13 10.4 1.6
14 (M) 0.22 0.16 15.0 2.3
15 (M) 0.23 0.1 13.3 2.1
16 (F) 0.44 0.12 225 34.7
17 (F) 0.24 0.11 19.6 3.0
18 (F) 0.17 0.19 13.6 2.1
19 (F) 0.25 0.16 43.4 6.7
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3. Abzymes with RNase activity
It was shown in several articles that IgGs from the sera of healthy humans cannot hydrolyze 
RNA [87–90]. At the same time, IgGs from the sera of patients with SLE, MS, Hashimoto’s 
thyroiditis and some other autoimmune pathologies effectively hydrolyze different ribopoly-
nucleotides and tRNAs [87–90].
Electrophoretically and immunologically homogeneous IgGs purified from the sera of 35 SCZ 
patients according to [75–83] as described above were used [91]. On the first step, we used 
a mixture of equal amounts of 35 polyclonal IgGs (scz-IgGmix) and 15 healthy donors. Then, we checked the fulfillment of the strict criteria described above. The homogeneity of the typi-
cal 150-kDa IgGmix was confirmed by SDS-PAGE with silver staining similar to Figure 1. The activity peak of the IgGmix treated with acidic buffer (pH 2.6) coincided under gel filtration exactly with the peak of intact Abs (Figure 2A) Immobilized polyclonal mouse IgGs against 
the light chains of human IgGs completely bind the RNase activity. Scz-IgGmix was subjected to SDS-PAGE in a gel co-polymerized with polymeric yeast RNA, and its RNase activity was 
revealed after the gel incubation in the standard reaction buffer only in the position of intact 
scz-IgGmix. (Figure 2B). Canonical human RNases have significantly lower molecular masses (13–15 kDa) than the intact IgGs (150 kDa). Therefore, the activity detection in the gel zones 
Number of patients (sex) Abs to dsDNA, 
A
450
/ml
Abs to ssDNA, 
A
450
/ml
Relative hydrolysis of 
DNA, %
k
cat
 ×105,min−1
1 2 3 4
Positive symptoms (PS)
20 (F) 0.24 0.15 0 0
Average (NS)** 0.28±0.07 0.16±0.03 34.0±40.1 5.3±6.2
M (IQR) (NS) 0.24 (0.06) 0.16 (0.07) 13.4 (19.6) 2.1 (3.0)
Average, total group 0.25±0.07 0.23±0.13 45.1±50.4 7.0 (7.9)
M (IQR), total groupΥ 0.23 (0.07) 0.16±0.1 13.4 (22.1) 2.1 (3.4)
Correl. coeff. (NS) 1–2 (0.3) 1–3 (0.5) 2–3 (0.35)
Correl. coeff., complete 
group
1–2 (0.3) 1–3 (0.4) 2–3 (0.62)
*For each value, a mean of three measurements is reported; the error of the determination of values did not exceed 7–10%.
**Average values are reported as mean ± S.E; they were recalculated to standard conditions and complete hydrolysis of 
18 μg/ml scDNA after 1 h of incubation in the presence of 0.1 mg/ml IgG was taken for 100%.
***The average apparent k
cat
 values of the reaction of DNA hydrolysis were calculated using average RA values: k
cat
 = V 
(M/min)/ [IgGs] (M), 18 μg/ml scDNA was used.
μStatistical significance of differences in DNase activity between schizophrenia patients with positive and negative 
symptoms (P = 0.026).
ϒThe median (M) and interquartile ranges (IQR) were calculated using the Mann-Whitney test.
Table 1. The relative concentration of fnti-DNA Abs, RAs (%), and the apparent k
cat
 values characterizing hydrolysis of 
scDNA by IgGs from the sera of SCZ patients.*
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of only intact scz-IgGmix together with the absence of any other activity and protein bands 
(Figure 2B) guarantee direct evidence that schizophrenia IgGs cleave RNA and IgGs are not 
contaminated by canonical RNases. Several other strict criteria were also fulfilled (see below).
Figure 2. Verification of the strict criteria to prove that the RNase activity of IgGs is an intrinsic property of IgGmix. FPLC gel filtration of scz-IgGmix on a Superdex 200 column equilibrated with an acidic buffer (pH 2.6) after its pre-incubation in the same buffer (A): (—), absorbance at 280 nm (A280); (∆), relative activity (RA, %) of IgGmix in the cleavage of RNA. A complete hydrolysis of poly(C) for 7 h was taken for 100%. The error in the initial rate estimation from two experiments 
in each case did not exceed 7–10%. Assay of RNase activity of scz-IgGmix in-gel containing polymeric yeast RNA (lane 2). RNase activity was detected after gel staining with ethidium bromide as a dark band on the fluorescent background. 
A gel part was stained with Coomassie R250 to show the position of intact scz-IgGmix (lane 1). Lane C corresponds to molecular mass markers. Relative activity of individual IgGs of patients with positive (C) and negative (D) symptoms of 
SCZ in the hydrolysis of yeast RNA, poly(A), poly(C), and cCMP.
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The relative activities of IgGs significantly varied from patient to patient. However, all 15 
samples of patients with positive and 16 ones with negative symptoms of SCZ demonstrated 
detectable or high RNase activity (Figure 2C and D). The relative average activity for patients 
with SCZ positive symptoms varied essentially (M/1 h/mg IgG): cCMP (0.31–1.56; average 
value (AV) = 1.05 ± 0.43), poly(C) (0.17–1.23 AV = 0.4 ± 0.29), poly(A) (0.09–0.4; AV = 0.25 ± 0.09), 
and yeast total RNA (0.08–0.46 AV = 0.18 ± 0.1) (Figure 2C). Similar situation was observed for 
patients with negative symptoms (M/1 h/mg IgG): cCMP (0.52–1.18; AV = 0.99 ± 0.18), poly(C) 
(0.1–0.68, AV = 0.41 ± 0.2), poly(A) (0.11–0.52; AV = 0.20 ± 0.11), and yeast total RNA (0.4–3.1 
AV = 1.68 ± 0.71) (Figure 2D). The difference in average activities of IgGs from patients with 
positive and negative symptoms was very small: cCMP (1.1-fold), poly(C) (1.03-fold), poly(A) 
(1.3-fold), and yeast total RNA (1.1-fold). According to non-parametric Kruskal-Wallis  analysis, 
Figure 3. Dependencies of average activities of IgGs of four groups of SCZ patients with different age in the hydrolysis 
of cCMP (A) and poly(C) (B).
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in none of these cases, there was a statistically significant difference (P > 0.2). Interestingly, a 
clear correlation of the RNase RAs with the duration of SCZ was not observed (P = −0.015 ± 0.14) 
except with activity of IgGs in poly(C) hydrolysis (+ 0.47). The tendency of increase in activity 
of IgGs in the hydrolysis of cCMP and poly(C) with age of SCZ patients was revealed (Figure 3). 
A statistically significant difference in the mean values of the relative activity in the case of 
cCMP hydrolysis was observed for a group of patients younger than 30 and over 50 years 
old (P = 0.03) (Figure 3A). For activity in poly(C) hydrolysis, statistically significant differ-
ence was revealed between the groups younger 30 and 30–40 (P = 0.034) as well as group of 
patients over 50 years old (P = 0.014) (Figure 3B). In addition, a good statistically significant 
correlation was observed between the activity in hydrolysis of cCMP (CC = + 0.896) and com-
posite index of SCZ, demonstrating a difference between parameters of positive symptoms 
and negative symptoms and showing the prevailing symptoms. Interestingly, a moderate but 
statistically significant negative correlation was observed between the efficiency of poly(C) 
hydrolysis and PANSS + (or PANSS Positive scale) evaluating signs that are redundant in 
relation to normal mental status (−0.43).
4. Hydrolysis of microRNAs
As mentioned above, some microRNAs regulate up to several hundred genes in the pathogene-
sis of SCZ [34–41]. We have analyzed the hydrolysis by SCZ abzymes’ four known microRNAs 
playing an important role in SCZ [91]. Figures 4–7 demonstrate typical patterns of miR-137, miR-
9-5p, miR-219-2-3p, and miR-219a-5p hydrolysis; specific % of the hydrolysis for each IgG and 
the average percent of microRNAs hydrolysis by 21 different Abs were estimated. Percentage 
of the microRNA hydrolysis by different IgGs in the same conditions varied and average values 
decreased in the following order: miR-219a-5p (the range: 7.4–99.7%, AV = 71.0 ± 32.7%) ≥ miR-
137 (14.9–99.9%, AV = 66.2 ± 29.2%) ≥ miR-9-5p (3.1–99.9%, AV = 56.7 ± 32.9%) ≥ miR-219a-2-3p 
(7.4–99.7%, AV = 52.4 ± 34.5%) (Figures 2–5). The correlation coefficients between sets of RAs in 
the hydrolysis of all 4 microRNAs are quite high, 0.84–0.93.
Spatial structures of microRNAs having minimal energy were calculated; Figure 8A–D show 
position of major, moderate, and minor sites of four microRNA hydrolysis by different IgGs 
(average % of the RNAs hydrolysis by 21 IgG preparations) [91]. One can see that three major 
sites of microRNAs hydrolysis are located in their loops or duplex parts directly articulated 
with the loops. The major sites of the hydrolysis of four microRNAs are different, but more 
often the cleavages occur after or before G-base: miR-219a-5p—6G-7U; 13C-14G, and 8C-9C; 
miR-137—5 U-6G, 8 U–9 U, and 10A-11A; miR-9-5p—6G-7G, 8 U–9 U, and 13 U-14A; miR-
219a-2-3p—5 U-6 U, 8 U-9G, and 13G–14G (Figure 8).
We have estimated the K
m
 and Vmax (kcat) values for microRNA hydrolysis using different preparations [91]. The dependencies of the initial rate on the microRNA concentration in 
the reaction catalyzed by IgGs were consistent with Michaelis-Menten kinetics. The K
m
 and 
k
cat
 values were to some extent comparable for all microRNAs: miR-137, K
m
 = 3.5 ± 0.2 μM, 
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k
cat
 = 0.14 ± 0.009 min−1; miR-9-5p, K
m
 = 2.4 ± 0.13 μM, k
cat
 = 0.083 ± 0.003 min−1; miR-219-2-3p. 
K
m
 = 1.7 ± 0.12 μM, k
cat
 = 0.10 ± 0.008 min−1; miR-219a-5p K
m
 = 4.5 ± 0.2 μM, k
cat
 = 0.17 ± 0.02 min−1.
Many anti-DNA Abs are directed against histone-DNA nucleosomal complexes appearing 
from internucleosomal cleavage during apoptosis [62]. In addition, cell apoptosis leads to the 
increase in blood the concentration of different nucleases, RNA and its complexes with  various 
Figure 4. The patterns of flu- miR-219a-5p (0.01 mg/ml) hydrolysis by IgGs (0.1 mg/ml) from sera of 21 SCZ patients. 
The hydrolysis products were detected by their fluorescence due to the fluorescent residue (flu) on their 5′-ends. The 
numbers of antibodies, lengths of the products, and the percentage of microRNA hydrolysis by each preparation are 
indicated in panels A and B.
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proteins. It was shown that the formation of DNA- and RNA-hydrolyzing Abs occurs after 
immunization of rabbits with RNA, DNA, DNase I, DNase II, and pancreatic RNase [92–96]. 
In addition, several monoclonal IgGs against B-DNA of different sequences (from SLE mice) 
efficiently hydrolyze ss- and dsRNA and DNA in a sequence-independent manner and the 
Figure 5. The patterns of Flu-miR-9-5p (0.01 mg/ml) hydrolysis by IgGs (0.1 mg/ml) from sera of 21 different SCZ patients. 
The hydrolysis products were detected by their fluorescence due to the fluorescent residue (Flu) on their 5′-ends. The 
numbers of antibodies, lengths of the products, and the percentage of microRNA hydrolysis by each preparation are 
indicated in panels A and B.
Psychotic Disorders - An Update116
RNase activity was by a factor of 30–100 higher than that of DNA [97]. Thus, DNase and 
RNase abzymes can appear in the blood of autoimmune patients due to several very different 
ways. Since IgGs hydrolyze different homo-polynucleotides and cleavage of four microRNA 
is site-specific (Figures 4–8), one can assume that some sets of RNase abzymes may be specific 
for some RNAs, while others are not.
Figure 6. The patterns of Flu-miR-137 (0.01 mg/ml) hydrolysis by IgGs (0.1 mg/ml) from sera of 21 different SCZ patients. 
The hydrolysis products were detected by their fluorescence due to the fluorescent residue (Flu) on their 5′-ends. The 
numbers of antibodies, lengths of the products, and the percentage of microRNA hydrolysis by each preparation are 
indicated in panels A and B.
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It was shown that 90–95% of Abs SLE and MS patients effectively hydrolyze DNA [47–56]. It 
was shown that a very high percent IgGs of SCZ patients (80–82%) are active the hydrolysis 
of DNA [83]. At the same time, similar to SLE and MS [47–56], all 100% schizophrenia IgGs 
effectively hydrolyze different RNAs [91]. It was shown previously that the appearance of 
abzymes hydrolyzing DNA and RNA is among the clear and earliest signs of autoimmune 
reactions [47–56]. In addition, light chains of IgGs from schizophrenia patients are similar to 
Figure 7. The patterns of Flu-miR-219a-2-3p (0.01 mg/ml) hydrolysis by IgGs (0.1 mg/ml) from sera of 21 different SCZ 
patients. The hydrolysis products were detected by their fluorescence due to the fluorescent residue (Flu) on their 5′-ends. 
The numbers of antibodies, lengths of the products, and the percentage of microRNA hydrolysis by each preparation are 
indicated in panels A and B.
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Figure 8. The average efficiency of four micro-RNAs hydrolysis by 21 IgG preparations in all sites of their cleavage 
(A–D). The position of major and moderate sites of different RNAs hydrolysis is shown.
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those of SLE patients, but not to these chains of healthy donors [83]. These data indicate that 
in patients with SCZ similar to SLE, MS, and other AIDS, there is a trespassing of the immune 
system leading to the production of abzymes with DNase and RNase activities.
5. Hydrolysis of myelin basic protein
Serum anti-MBP Abs in MS and SLE patients were reported in several articles [75, 76, 79–81, 
98, 99]. The relative levels of antibodies against MBP in the sera of 28 patients with SCZ and 
15 healthy donors were compared by ELISA (Table 2). The concentrations of auto-Abs against 
MBP for healthy donors were not zero and changed from 0.02 to 0.16 А450 units, in average 0.09 ± 0.04 А450 units [75, 76, 79–81, 100, 101]. Relative indexes of anti-MBP Abs for 28 SCZ patients varied from 0.04 to 0.26 А450 units, in average 0.16 ± 0.068 А450 units. For patients with positive symptoms of SCZ, average value (0.18 ± 0.066 А450 units) was 1.3-fold higher than that for patients with negative symptoms (0.14 ± 0.067 А450 units), but this difference was statistically 
Number of patients 
(Sex)
Abs to MBP, A
450
/ml Relative % of 
hydrolysis
k
cat
 × 103, min−1
Positive symptoms of SCZ
Parameters 1 Parameters 2
1 (M) 0.32* 10.5** 9.8***
2 (M) 0.24 50.0 46.8
3 (M) 0.13 20.5 19.2
4 (M) 0.07 0.5 0.5
5 (F) 0.13 1.0 1.0
6 (F) 0.18 18.5 17.3
7 (F) 0.15 15.0 14.0
8 (F) 0.09 0.5 0.5
9 (F) 0.17 17.5 16.4
10 (F) 0.20 4.5 4.2
11 (F) 0.18 15.0 14.0
12 (M) 0.14 0 0
13 (F) 0.20 0 0
14 (M) 0.26 0 0
Average value 0.18 ± 0.066 11.0 ± 13.7 10.3 ± 12.9
Negative symptoms of SCZ
Parameters 3 Parameters 4
15 (M) 0.17* 50.0** 46.8***
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insignificant (P = 0.27). Using the same approach and test system, it was previously shown that 
average index of anti-MBP antibodies for 25 MS patients is 0.8 ± 0.1 А450 units [79] and, for SLE patients, it is 0.38 ± 0.08 А450 units [75]. Thus, all SCZ patients analyzed by us demonstrated ~1.8-fold higher level of serum anti-MBP Abs than healthy individuals, but ~2.4-fold and 5.0-
fold lower level than SLE and MS patients, respectively.
Electrophoretically and immunologically homogeneous polyclonal IgGs were separated from 
the sera of 28 SCZ patients and 15 healthy donors as described above. The homogeneity of 
the 150 kDa scz-IgGmix and healthy-IgGmix (mixtures of equal amounts IgGs from the sera of 28 SCZ patients and 15 healthy volunteers, respectively) was confirmed by SDS-PAGE similar 
to [83] Figure 1A.
We have applied several of known rigid criteria described above. The most important of these 
criteria are given below: (1) electrophoretic homogeneity of scz-IgGmix (Figure 1A); (2)  complete 
Number of patients 
(Sex)
Abs to MBP, A
450
/ml Relative % of 
hydrolysis
k
cat
 × 103, min−1
Positive symptoms of SCZ
Parameters 1 Parameters 2
16 (M) 0.19 49.5 46.3
17 (F) 0.22 13.5 12.6
18 (M) 0.17 47.0 44.0
19 (M) 0.08 50.0 46.8
20 (F) 0.04 25.0 23.4
21 (F) 0.17 10.5 9.8
22 (M) 0.26 14.0 13.1
23 (F) 0.03 26.5 24.8
24 (M) 0.11 6.5 6.1
25 (F) 0.18 43.5 40.7
26(F) 0.16 43.5 40.7
27 (F) 0.08 0.0 0.0
28 (M) 0.12 0.0 0.0
Average value 0.14 ± 0.067 27.1 ± 19.6 25.4 ± 18.4
Correl. coefficient Parameters 1 and 2 (0.28), Parameters 3 and 4 (0.10); Parameters 1 + 3 and 2 + 4 (0.04)
*For each value, a mean of three measurements is reported; the error of the determination of values did not exceed 7–10%.
**Average values are reported as mean ± S.E; they were recalculated to standard conditions and complete hydrolysis of 
0.33 mg/ml MBP after 5 h of incubation in the presence of 0.1 mg/ml IgG was taken for 100%.
***The average apparent k
cat
 values in the reaction of MBP hydrolysis were calculated using average RA values (% of the 
hydrolysis at fixed concentration of MBP**): k
cat
 = V (M/min)/ [IgGs] (M).
Table 2. Numbers of SCZ patients, their sex, and relative characteristics of patients antibodies.
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Figure 9. FPLC gel filtration of scz-IgGmix on a Superdex 200 column in an acidic buffer (pH 2.6) after IgGs pre-incubation in the same buffer (A): (—), absorbance at 280 nm (A280); (■), relative activity (RA, %) of IgGs in the hydrolysis MBP. A complete hydrolysis of MBP for 5 h was taken for 100%. Assay of MBP-hydrolyzing activity of purified scz-IgGmix after SDS-PAGE in gradient 4-15 % gel, the gel was incubated under special conditions for renaturation of Abs (B). MBP (0.4 
mg/ml) was incubated with 0.1 mg/ml scz-IgGmix for 24 h (lane 1) or scz-IgG-1 (lane 2) and with healthy-IgGmix (lane 3) or individual healthy-IgG-1 (lane 4), as well as in the absence of Abs (lane C). The RA (%) was revealed using the extracts of 
2-3-mm many fragments of one longitudinal slice of the gel (C). The second control longitudinal slices of the same gels 
corresponding to IgGmix before (lane 1) and after (lane 2) treatment with DTT were stained with Coomassie R250 (D). Analysis of possible hydrolysis of bovine serum albumin (BSA) (E) and hen egg lysozyme (Lys) (F) by scz-IgGmix purified on MBP-Sepharose (lanes 1). Lanes 2-9 correspond to nine individual scz-IgGs, while lanes C to the proteins incubated 
in the absence of Abs (E and F).
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adsorption of IgGmix hydrolyzing MBP by anti-IgG Sepharose leading to a disappearance of the catalytic activity of the solution; (3) FPLC gel-filtration of scz-IgGmix under conditions of “acidic shock” (pH 2.6) lead to revealing of the activity only in the peak corresponding exactly 
to 150 kDa IgGs (Figure 9A); (4) in contrast to scz-IgGmix, healthy-IgGmix did not hydrolyze MBP 
(Figure 9B); (5) Scz-IgGmix purified on MBP-Sepharose hydrolyzed only MBP and was inac-tive in the hydrolysis of control proteins, bovine serum albumin (Figure 9C), and lactoferrin 
(Figure 9D); (6) scz-IgGmix was separated by SDS-PAGE, and their MBP-hydrolyzing activity was estimated after the extraction of proteins from the separated gel slices (Figure 9E and F). 
The electrophoretic mobility of low molecular mass canonical proteases (24–25 kDa) cannot 
coincide with that of intact IgGs (150 kDa). Therefore, the detection of protease activity in 
the gel fragments corresponding only to intact IgGs together with the absence of any other 
proteins and activity bands (Figure 9E and F) provides direct evidence that SCZ IgGs possess 
MBP-hydrolyzing activity.
The RAs of SCZ IgGs in the cleavage MBP was estimated from the decrease in the intensity 
of Coomassie-stained MBP band after electrophoresis according to [76–81]. For quantitative 
estimation of the proteolytic activity, we have found a relatively low concentration of each 
IgG sample (0.05–0.3 mg/ml) corresponding to the reaction of the first order (1–24 h; 15–45% 
of conversion). This approach allowed us to normalize the relative activity, like in the case of 
determination of the specific activity of enzymes [102], to standard condition; relative % of 
MBP hydrolysis after incubation for 5 h in the presence of 0.1 mg/ml (0.66 μM) IgGs.
Among 28 individual SCZ patients, the RAs of IgGs at a fixed concentration of MBP (0.33 mg/ml) 
were absent for five patients (17.9%): 3 of 14 patients (21.4%) with positive symptoms 
and 2 of 14 patients (14.3%) with negative symptoms (Table 1). The average relative activity 
(RA, %) and apparent k
cat
 values (k
cat
 = V/[IgG]) at fixed concentration of MBP (0.33 mg/ml; 
18.3 μM) were calculated (Table 2). The apparent k
cat
 values characterizing hydrolysis of MBP 
by 14 IgGs of patients with positive symptoms varied in the range 0–46.8 × 10−3 min−1 (average 
10.3 ± 12.9) × 10−3 min−1; M = 0.7 × 10−3, IQR = (0.5–16.4) × 10−3). The apparent k
cat
 values for 
14 IgGs of patients with negative symptoms also varied in the range 0–46.8.0 × 10−3 min−1 (average 
(25.4 ± 18.4) × 10−3 min−1; M = 24.1 × 10−3, IQR = (9.8–44.0) × 10−3). Overall, the average k
cat
 value 
of IgGs from patients with negative symptoms was approximately 2.5-fold higher than that for 
Abs of patients with positive symptoms (Table 2). The coefficient of correlation (CC) between 
the anti-MBP Abs titers (A450) and RAs of 28 Abs was very low, 0.04. At the same time, CC for these values in the case of patients with positive symptoms (0.28) was 2.8-fold higher than that 
for patients with negative symptoms (0.10) (Table 2). According to Wald-Wolfowitz test, there 
is a statistically significant difference between k
cat
 value of IgGs from patients with negative 
and positive symptoms (P = 0.034). Interestingly, the CC (0.7–0.79) between the anti-MBP Abs 
titers (A450) and RAs of Abs from SLE patients [8] was significantly higher than for SCZ patients.
It has been recently shown that abzymes against MBP from the sera of MS patients hydrolyze 
MBP at several clustered sites localized within four known antigenic determinants of human 
MBP and that four oligopeptides corresponding to these determinants of MBP are encepha-
lytogenic and can play a negative role in the MS pathogenesis [79–82]. It is important that anti-
MBP abzymes from the sera of SLE, MS, and SCZ patients hydrolyze MBP at the same four 
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sites of antigenic determinants and effectively cleavage all four 17–25-mer OPs corresponding 
to these four determinants [75–80]. It was shown, that anti-MBP abzymes of SCZ patients can 
also cleavage these four OPs: OP21 and OP25 were the best substrates of SCZ abzymes.
We have estimated the K
m
 and k
cat
 values for the hydrolysis of MBP, OP21 (YLASASTM-
DHARHGFLPRRHR) and OP25 (AQGTLSKIFKLGGRDSRSGSPMARR) in the case of two indi-
vidual preparations of SCZ patients. The initial rate data obtained at increasing MBP, OP21, and 
OP25 concentrations were consistent with the Michaelis-Menten kinetics. Different abzymes usu-
ally demonstrate a significantly higher affinity to substrates in comparison with canonical proteases 
[45–56]. The affinity of intact MBP for SCZ IgGs was (in terms of K
m
 values) in the range of 4.3–12.4 μM 
(Table 2), which corresponds to typical K
d
 (and K
m
) values for Ab-antigen interactions. These K
m
 
values for MBP of SCZ abzymes are to some extent comparable with the K
m
 for MBP (~0.6–2.7 μM) 
reported previously for IgGs from SLE [75–78] and MS (0.9–5.0 μM) [81] patients. Interestingly, 
the K
m
 values for scz-IgGs in the case OP21 and OP25 (49–770 μM) are to some extent lower com-
pared with those for four OPs in the case of SLE. As it mentioned above, a detectable level of MBP-
hydrolyzing abzymes was shown to be as an indicator of pre-disease, while increase in the activity 
of obvious pathology conditions of typical spontaneous or induced autoimmune diseases [63–68].
It was shown that DNase and RNase abzymes of autoimmune patients present a “cocktail” of 
Abs directly to DNA and RNA or their complexes with proteins and anti-idiotypic Abs against 
active centers of DNase I, DNase II, RNase and other enzymes hydrolyzing nucleic acids 
[92–96]. MBP-hydrolyzing Abs are produced from animals immunization with MBP and its 
encephalytogenic peptides [66–68]. In addition, immunization of experimental autoimmune 
encephalomyelitis (EAE) mice, a model of human MS, with myelin oligodendrocyte glycopro-
tein (MOG35–55) leads to the production of both MBP- and DNA-hydrolyzing abzymes [66–68].
6. Abzymes with oxidation-reduction activities
Several publications show that some abzymes may form not only in patients with autoimmune 
pathologies but also in healthy humans. However, it is not currently clear which antigens can 
stimulate the formation of these abzymes in autoimmune patients and healthy donors.
Human organisms are constantly exposed to oxidative stress and various toxic components. 
The partially reduced oxygen species (O2−, H
2
O
2
, and OH•) produced in all higher organisms 
and appeared in bodies through exposure to different compounds to ionizing radiation. They 
act as dangerous oxidants attacking lipids, proteins, DNA, and other different cellular com-
ponents [103–107]. Oxidative damage of many cells has been considered as a very important 
pathophysiological factor in the development of many different diseases such as carcinogen-
esis, aging, multiple sclerosis (MS), and SCZ. It is believed that MS and SCZ have different 
pathogenetic mechanisms. MS is a neurodegenerative chronic disease of AI nature, associated 
with structural damage to the nerve fibers myelin sheath, while SCZ has neurotransmitter 
nature. It was, however, demonstrated that the oxidative stress activation is a major factor in 
the MS and SCZ [108–114]. In the case of SCZ, the cellular metabolism changes associated with 
alteration in the activity of enzymes including antioxidant enzymes were revealed [109, 112].
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Several enzymes protecting various organisms from oxidative stress are known. Mammalian, 
plant, and bacterial peroxidases, glutathione peroxidases, oxidoreductases, oxidases, and 
dismutases are mostly metal ions-dependent enzymes [107, 115–118]. Metal ions having the 
variable valence (more often: Fe2+, Cu2+, and Mn2+) participate in a transfer of electrons in the reactions of oxidation-reduction, catalyzed by enzymes [118].
A comparison of catalase, superoxide dismutase, H
2
O
2
-dependent peroxidase, and H
2
O
2
-
independent oxidoreductase activities of polyclonal IgGs obtained from the sera of healthy 
Wistar rats have been carried out [119]. Approximately, 83% of IgGs possess superoxide 
dismutase activity, but all IgGs oxidized 3,3′-diaminobenzidine in the presence (peroxidase 
activity) and the absence of hydrogen peroxide (oxidoreductase activity). Оnly 17% of rat 
IgGs were shown to possess catalase activity. It was shown that small fractions of IgGs and 
their F(ab)
2
 and Fab fragments of IgGs from sera healthy humans oxidize 3,3′-diaminoben-
zidine in the presence of H
2
O
2
 through a peroxidase and in the absence of H
2
O
2
 through an 
oxidoreductase activity [120, 121].
It was shown that some electrophoretically homogeneous IgGs (and their F(ab) and F(ab)
2
 
fragments) from the sera of patients with SCZ (36.4%) and from healthy donors (33.3%) 
possess catalase activity [122]. As in the case of the abzymes described above, it was shown 
that the catalase activity of all IgGs is their intrinsic property (Figure 10). The catalase RA of 
IgGs from the sera of individual of SCZ patients on average was 15.8-fold higher than that of 
healthy volunteers. After extensive dialysis against EDTA chelating metal ions of IgGs, the 
catalase RA of IgGs, on average decreases approximately 2.5–3.7-fold; all IgGs possess metal-
independent and dependent catalase activity.
External Me2+ ions added to non-dialyzed and dialyzed IgGs significantly increase their activ-
ity (Figure 11). Co2+is the best activator of non-dialyzed and dialyzed IgGs, the activation of 
IgGs by Mn2+, Cu2+, and Ni2+ ions is substantially lower than by Co2+. All IgGs demonstrate 
several individual different expressed pH optima in the pH range from 4.0 to 9.5. These data 
speak for the individual repertoire of catalase IgGs in every person and an extreme diversity 
of abzymes in their pH optima and activation by different metal ions.
In this connection, it should be marked that polyclonal IgGs against different antigens from 
the blood sera of patients with AI diseases and with different activities are usually very het-
erogeneous in their affinity for specific antigens and can be separated into many subfractions 
by chromatography on antigens-Sepharoses [75, 76, 79, 123]. Pools of polyclonal abzymes can 
contain different proportions of light chains of κ- and λ-types, Abs demonstrating different 
pH optima, having different net charges, metal-independent or activated by different metal 
ions, and characterized by different substrate affinities and specificities [17, 39–43, 124]. It 
was shown that small fractions of IgGs of all four subclasses (IgG1–IgG4) from autoimmune 
patients are catalytically active in the hydrolysis of different substrates [47–56]. For analysis 
of myelin basic protein- and DNA-hydrolyzing activities of monoclonal light chains (MLChs) 
corresponding to SLE phagemid library of kappa MLChs were used [125–129]. It was shown 
that some hundreds of different monoclonal light chains hydrolyze DNA and other ones 
cleavage myelin basic protein; all MLChs demonstrated very different physicochemical and 
enzymatic properties [125–129]. It should be assumed that the extraordinary diversity of these 
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Figure 10. Typical time-dependencies of the decrease in 30 mM H
2
O
2
 absorbance at 240 nm (A240) in the presence of 200 nM IgG-1 and IgG-11 as well as 2 nM IgG-8 corresponding to different individual patients (A). Checking of strict 
criteria proving that the catalase activity is intrinsic properties of scz-IgGmix. Preparations of scz-IgGmix (equimolar mixture of 22 samples) were separated by FPLC gel filtration on a Superdex 200 column in an acidic buffer Gly-HCl 
pH 2.6 after Abs pre-incubation using the same buffer (B): (o), relative activity (RA) of the IgGmix in the degradation of H
2
O
2
; (—), absorbance at 280 nm (A280); SDS-PAGE analysis of catalase activity of intact scz-IgGmix (C) as well as separated H, L chains and their L
n
H
n
 oligomers (E) in non-reducing SDS-PAGE using gradient 4–15%: Scz-IgGmix before (C) and 
after treatment of IgGmix with DTT (E); lane 1 of panel D corresponds to panel C and lane 2 to panel E. The RAs (A240/min) were revealed using the extracts of 2–3-mm fragments of one gel longitudinal slice of corresponding IgGmix before (C) and after treatment with DTT (E). The control longitudinal slices of the same gels were stained with Coomassie R250 
(D): lane 1 corresponds to intact IgGmix, lane 2 to IgGmix incubated with 40 mM DTT for 10 min at 30o C, lane 3 to IgGmix boiled with DTT. Lane C (D) shows the positions of molecular mass standard markers. The relative activity of F(ab) and 
F(ab)
2
 fragments of individual IgG-4, IgG-12, and IgG-14 (F). The average error of the initial rate determination from two 
experiments did not exceed 10–15%.
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monoclonal light chains is mainly due to the significant differences in their variable regions 
responsible for substrate specificity and catalysis [125–129]. Heterogeneity is also observed 
in intact catalytic IgGs with kappa light chains, and it was shown that structural diversity 
(heterogeneity) might exist due to the constant region domain and specific role of metal ions 
of the catalytic light chains [130, 131]. A similar result of extreme catalytic heterogeneity is 
observed for abzymes with catalase activity.
It has been shown that immunoglobulins from humans and various animals have superoxide 
dismutase activity; they convert singlet oxygen 1O2 into its reduced form O2• [132, 133]. These 
abzymes use H
2
O as an electron source and attach it to 1O2* to form H
2
O3 as the first intermediate of several consecutive stages leading to the formation of H
2
O
2
. These data are believed to 
Figure 11. Effect of the dialysis of IgGs against EDTA for two individual scz-IgGs and different metal ions on the relative 
activity (RA, %) of dialyzed and non-dialyzed preparations (A and B). The RA of every non-dialyzed preparation was 
taken for 100%. Dependencies of the relative catalase activity of scz-IgGs on pH of the reaction mixture (C and D). All 
RAs of Abs before its preincubation were taken for 100%. The relative activity of IgG-14 at pH 7.0 was taken for 100%. 
All IgG preparations, metal ions, and conditions used marked on panels A–D. The errors in the determination of initial 
rate from three experiments in each case did not exceed 7–10%.
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indicate the possibility of protecting mammalian organisms from 1O2* with Abs and raise the 
question of the possibility of a special evolution of immunoglobulins as a specific antioxi-
dants of blood [132, 133]. For immunoglobulins, a mechanism has been discovered by which 
oxygen can be recovered and reused in phagocytosis, which indicates the possibility of the 
Figure 12. Typical kinetic curves of accumulation of a colored product (A450) after DAB substrate oxidation by IgGs with peroxidase (in the presence of H
2
O
2
) (A) and with oxidoreductase (in the absence of H
2
O
2
) (B); activities in the oxidation 
of 3,3′-diaminobenzidine (0.2 mg/ml) in the case of 670 nM IgG-1 and IgG-6. Curve - IgG corresponds to the oxidation 
of the substrate in the absence of IgGs. SDS-PAGE analysis of peroxidase (o) and oxidoreductase (□) activities of IgGmix (20 μg) (C and D). After electrophoresis, the 4–15% gradient gel was treated using special conditions for renaturation of 
IgGmix. The RAs were evaluated using extracts of 40 gel fragments (2–3 mm); 20 μl of extracts were added to the standard mixtures and incubated for 24 h. The second band of the same gel was used to determine the position of intact IgGmix (D); the gel was stained with Coomassie R250.
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involvement of the immune system in microbial regulation. Even more surprising is the dis-
covery of abzymes of higher eukaryotes that catalyze the formation of ozone used by cells in 
phagocytosis [134]. Taking this into account, one can put that Abs with superoxide dismutase 
activity can catalyze the conversion of the superoxide radical into hydrogen peroxide, and the 
abzymes with catalase activity neutralize the harmful effect of H
2
O
2
.
It was shown that IgGs from the blood of healthy Wistar rats possess high H
2
O
2
-dependent per-
oxidase (hereinafter peroxidase) and H
2
O
2
-independent oxidoreductase (hereinafter oxidore-
ductase) activities in the oxidation of horseradish peroxidase substrate—3,3′-diaminobenzidine 
and some other aromatic amines, phenols, and quinones [135–138]. Interestingly, the same 
activities were detected in IgG from the blood of healthy people [120, 121]. The relative peroxi-
dase activity of IgG of healthy people in the absence of external metal ions varies very much 
from donor to donor, but on average, it is about five times lower than in rat IgGs [120, 121].
Electrophoretically and immunologically homogeneous preparations of IgG antibodies were iso-
lated from blood sera of 18 patients with SCZ and 14 healthy donors by affinity chromatography 
on Protein G-Sepharose followed by high-efficiency gel filtration as described above. Using rigid 
criteria, it was shown that the oxidation of substrates is an intrinsic property of these polyclonal 
antibodies (Figure 12). The comparison of H
2
O
2
-dependent peroxidase and H
2
O
2
-independent 
oxidoreductase activities of IgGs of SCZ patients and healthy donors in the oxidation of 
3,3′-diaminobenzidine was carried. All IgG preparations of SCZ patients and healthy donors 
had these activities, but the apparent k
cat
 values varied in a very wide range (16.2–355.8 min−1).
On average, the rate of oxidation of the substrate in the presence of H
2
O
2
 from the sera of SCZ 
patients and healthy donors was 1.3–1.5 times higher than in the absence of H
2
O
2
. The dif-
ference between the average peroxidase (1.8-fold) and oxidoreductase (1.5-fold) IgG activity 
from the sera of SCZ patients and healthy donors was statistically significant (P = 0.008). At the 
same time, the correlation coefficient of peroxidase and oxidoreductase activity of abzymes of 
SCZ patients was significantly higher (0.66) than for healthy donors (0.27).
The blood of healthy donors and patients with various autoimmune diseases including SLE 
and MS usually contains abzymes with amylase and ATPase activities [47–56]. In addition, the 
spontaneous and DNA-induced development of deep SLE-like pathology associated with a 
specific reorganization of the immune system in the case of autoimmune-prone MRL-lpr/lpr 
mice, leads to a production of IgGs hydrolyzing DNA, ATP, and polysaccharides [64, 65]. It 
was surprising that in the case of 18 patients with SCZ, amylase activity was detected only in 
IgG antibodies from one patient, but all 18 preparations were inactive in ATP hydrolysis. This 
indicates the possibility of the production of abzymes to various antigens in the case different 
autoimmune diseases.
7. Comparison of abzymes of patients with SCZ and other 
pathologies
It has been shown that antibodies hydrolyzing DNA, proteins, ATP, and polysaccharides can 
be considered the earliest and statistically significant markers of autoimmune pathologies in 
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human patients and experimental mice with autoimmune diseases [47–56, 64–69]. Abzymes 
are found already in the early stages of different diseases when there are no visible markers of 
specific AIDs, and changes in proteinuria, auto-antibodies titers correspond to typical ranges 
of these indicators for healthy individuals. The detection of abzymes is significantly more 
sensitive than the detectable ELISA markers since catalysis is characterized by the develop-
ment of the reaction product due to a large number of enzyme turns and the possibility of 
increasing the catalyst turnover due to the increase in the reaction time. It makes possible to 
detect even small amounts of abzymes in preparations of polyclonal Abs with a relatively low 
but reliably tested activity.
Antibodies against DNA were detected in an increased concentration, compared with that in 
healthy donors, in only 17–18% of patients with MS and 37% of patients with SLE [57], while 
DNA-hydrolyzing Abs in 90–95% of patients with MS [74] and SLE [72, 73]. This is because 
the increase in auto-Abs titers in patients with AIDs occurs only in the late stages or with exac-
erbations of these diseases. Thus, reliable detection of abzymes, from our point of view, can 
be considered as an indicator of even a painful condition (the onset of pathology), and even 
more development of spontaneous or induced AIDS [47–56, 64–69].
To diagnose MS, a number of medical Poseur criteria are usually used [139, 140], but the final 
reliable diagnosis is made after the tomography showing “plaques” in the brain that appear in 
the late stages of the disease. The presence of anti-DNA Abs in patients with MS traditionally 
was considered only as one of the additional evidences of a system imbalance in immuno-
regulation, which has no independent pathogenetic significance. However, only anti-DNA 
Abs as the main component of the intracerebral IgG response was found directly in the brain 
plaques and the cerebrospinal fluid, and they bind to the surface of neuronal cells and oligo-
dendrocytes [141]. These data were interpreted as evidence of the leading role of anti-DNA 
Abs in the pathogenesis of MS [141].
Despite the absence of signs that meet the criteria of Poseur, we assumed a preliminary diag-
nosis of the “initial stage of MS” in the case of three patients [69], since they demonstrated Abs 
with high DNase activity in their blood. Approximately 1.5 years later, the indicators of these 
patients began to meet the criteria of Poseur and after 2–3 years, the patients had “plaques” 
in the brain.
In this connection, it should be mentioned that the sera of healthy donors do not contain 
Abs with DNase, RNase, and MBP-hydrolyzing activities [47–56]. In addition, there were no 
detected abzymes with such activities in patients with weak autoimmune reactions. Currently, 
IgGs and/or IgAs and IgMs hydrolyzing DNA/RNA have been revealed in the sera of patients 
with SLE [72, 73, 142, 143], Hashimoto thyroiditis [144], diabetes mellitus [53], MS [74, 145, 
146], tick-borne encephalitis [147], and HIV infection [148] demonstrating strong autoimmune 
reactions. As it was shown on the example of Hashimoto thyroiditis, the typical therapy of 
patients with thyroxine resulted only in a temporary change of the hormone concentration in 
the blood but did not affect the level of DNase abzymes. However, treatment of patients with 
an immunosuppressive drug Plaquenil leads to a significant decrease in DNase antibodies 
associated with an increase in concentrations of thyroid hormone, elevation of the thyroid 
gland functional activity, and improvement of the patient’s clinical state [144].
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It should be mentioned that the average concentration of Abs interacting with dsDNA for 
SCZ patients (0.25 ± 0.07 A450/ml) is 2.5-fold higher than that for healthy donors (0.1 ± 0.02 A450/ml), but lower than for MS (0.39 ± 0.26 A450/ml) and SLE (0.66 ± 0.48 A450/ml) patients [53–56]. At the same time, concentrations of anti-DNA antibodies in comparison with healthy 
donors are higher in 30% patients with SCZ, which is comparable with that for SLE patients 
(37%) [83]. In addition, 80% IgGs of SCZ patients possess detectable or high DNase activity. 
Moreover, all 100% of IgGs of SCZ patients have RNase activity, and they can hydrolyze not 
only different polynucleotides and cCMP, but also specific for this pathology microRNAs 
[83]. Thus, these data point to the development of autoimmune processes in patients with 
schizophrenia similar to those of classical AIDS: SLE and MS [83].
Interestingly, SCZ patients demonstrated ~1.8-fold higher level of serum anti-MBP Abs than 
healthy individuals, but ~2.4- and 5..50-fold lower than those for SLE and MS patients, respec-
tively [75]. A feature people with MS and SLE is the development of abzymes hydrolyzing not 
only DNA, but also MBP and polysaccharides [75–82]. It was shown that IgGs from the sera 
and cerebrospinal fluid (CSF) of MS patients are active in the hydrolysis of MBP, DNA, and 
polysaccharides [149–151]. In contrast to healthy donors, Abs from the sera of 82% of patients 
with SCZ showed a reliably tested or high activity in the hydrolysis of MBP [100, 101]. As men-
tioned above, the researchers of the London medical Institute Oliver House advanced theory, 
according to which schizophrenia is the result of a lesion of immune system of the brain. The 
set forth above data reveals a number of similarities between SCZ and MS.
In this connection, it should be mentioned that development of SLE in autoimmune-prone MRL-
lpr/lpr mice and changes in EAE-like (experimental autoimmune encephalomyelitis) parameters 
in C57BL/6 mice can occur spontaneously and may be accelerated by immunization of mice with 
DNA [63–65] or with MOG [66–68], respectively. It was shown that IgGs from the sera of control 
C57BL/6 mice are catalytically inactive. During spontaneous development of EAE, a specific 
reorganization of the immune system of mice occurred leading to a condition which was asso-
ciated with the generation of catalytically active IgGs hydrolyzing MBP, MOG (myelin oligo-
dendrocyte glycoprotein) and DNA. These processes are associated with increased proteinuria, 
changes in the differentiation of mice bone marrow hematopoietic stem cells and an increase in 
proliferation of lymphocytes in bone marrow, spleen, and thymus as well as a significant sup-
pression of cell apoptosis in these organs. The strongest alterations were found after mice immu-
nization with MOG. Thus, a significant increase in DNase and protease activities of abzymes 
were shown to be the earliest statistically significant marker of EAE development. In connection 
with these, it is important to note that abzymes hydrolyzing DNA, MBP, and oligosaccharides 
were found in cerebrospinal fluid of MS patients and their activity on average approximately 
from 30 to 60-fold higher than those from the sera of the same patients [149–151]. This may 
indicate that the development of autoimmune processes can begin already in the human brain.
In MS, SLE, and SCZ, anti-MBP abzymes can attack MBP of the myelin-proteolipid sheath of 
axons leading to a disturbance of conduction of nerve impulses [53–56]. Overall, the destruc-
tion of the myelin sheath and the production of MBP-hydrolyzing Abs can be a common 
phenomenon for some different diseases including SCZ. Interestingly, neuropsychiatric 
involvement to some extent similar to MS and SCZ patients occurs in approximately 50% 
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patients with SLE and carries a poor forecast [152]. SLE mostly affects the central neural sys-
tem, and within its cerebral complications, it has a particular propensity—perhaps more than 
any other systemic inflammatory disease—to cause psychiatric disorders. Some similar neu-
ropsychiatric indicators of disease common to SLE, MS, and SCZ were observed [152]. The 
production of abzymes hydrolyzing MBP as well as DNA and RNA even more powerful 
indicate the development of significant autoimmune reactions in patients with SCZ. Thus, in 
different patients with SCZ, SLE, and MS, there are, in some extent, similarities in the viola-
tion of the immune system, production of abzymes, and neuropsychiatric disorders.
As it indicated above, the sera of healthy donors contain abzymes with different oxidation-
reduction activities. Therefore, at first glance, the detection of abzymes with such activities in 
patients with SCZ may not have a pathophysiological significance. However, in SCZ patients, 
a dysfunction of the glutamatergic system is shown [9–12], while misbalance of dopamine-
glutamate homeostasis can result in the patient’s development of generalized oxidative stress 
[13, 14]. In SCZ patients, the cellular metabolism changes are associated with alteration in the 
activity of enzymes, including antioxidant enzymes [109, 112].
The difference between the average peroxidase (1.8-fold) and oxidoreductase (1.5-fold) IgG 
activity in the oxidation of 3,3′-diaminobenzidine from the sera of SCZ patients and healthy 
donors was moderate but statistically significant (P = 0.008). At the same time, the average 
relative catalase activity of IgGs from the sera of SCZ patients was 15.8-fold higher than from 
healthy donors. These data on the oxidation-reduction enzymatic activities of antibodies 
seem to be important for understanding the possibility of protecting a person from oxidative 
stress with the help of blood immunoglobulins.
8. Conclusion
It was shown that similar to patients with typical autoimmune pathologies, SLE and MS, 
sera of SCZ patients contain IgGs hydrolyzing DNA, RNA, MBP, and abzymes with catalase, 
peroxidase, and oxidoreductase activities. As mentioned above, an appearance of abzymes 
with nuclease and protease activities, which are absent in the blood of healthy donors, may be 
used as the earliest markers of autoimmune reactions in patients with different autoimmune 
diseases. Therefore, one cannot exclude that abzymes with these activities may in addition 
to other different important factors cooperatively promote activation of neuropathologic and 
psychiatric mechanisms in SCZ pathogenesis.
SCZ patients show some similarity with MS and SLE patients in the development of the same 
medical, biochemical, and immunological indexes appearing especially in late stages of these 
diseases. Thus, it is obvious that early diagnostics of SCZ requires the use of all known inde-
pendent methods to exclude SLE, MS, and probably other possible diseases leading to a for-
mation of MBP-, DNA-, and RNA-hydrolyzing abzymes. However, even revealing of these 
abzymes on early stages of SCZ may be very useful for detecting of autoimmune reactions 
in such patients. It is known that SLE, MS, and SCZ patients are usually treated with differ-
ent drugs. SCZ is known as the progressive mental illness with very different polymorphic 
symptoms, which are similar to typical autoimmune diseases associated in addition with 
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autoimmune reactions. Taking this into account, one cannot exclude that for a more effective 
treatment of schizophrenia, patients may be necessary to use some kind of medications sup-
pressing the autoimmune reactions in this pathology. For example, it should be emphasized 
that the activity of MBP-hydrolyzing Abs attacking myelin-proteolipid shell of axons may be 
inhibited by MS therapeutic Copaxone [82].
DNase abzymes form SLE and MS patients are cytotoxic and induce apoptotic cell death. The 
decrease in activity of Abs with nuclease activities was achieved after treatment of patients 
with Hashimoto thyroiditis with Plaquenil [144]. It cannot be ruled out that any other drugs 
that are used to treat patients with other different autoimmune diseases can be effective in 
suppressing the autoimmune component in patients with schizophrenia.
In summary, as mentioned above, schizophrenia is not currently attributed to the typical 
autoimmune diseases. However, we have shown for the first time in several articles that poly-
clonal IgGs from the sera of schizophrenia patients possess DNase, RNase, MBP-hydrolyzing, 
catalase, peroxidase, and oxidoreductase catalytic activities, which are the earliest markers of 
autoimmune reactions. It means that immune system dysregulation including autoimmunity 
together with other factors can be important for the development of schizophrenia.
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